Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881733 | 0.94 | PTGER4 (0.56) | PTGER4PIK3C3HDAC1TDP1HDAC3 | |
| SCHEMBL1609124 | 0.88 | PTGER4 (0.48) | PTGER4PIK3C3HDAC1TDP1HDAC3 | |
| SCHEMBL3970983 | 0.88 | PTGER4 (0.50) | PTGER4PIK3C3HDAC1TDP1HDAC3 | |
| SCHEMBL584850 | 0.86 | PTGER4 (0.46) | PTGER4PIK3C3HDAC1TDP1HDAC3 | |
| SCHEMBL5881896 | 0.81 | PTGER4 (0.57) | PTGER4PIK3C3TDP1ALDH1A1LIPC | |
| SCHEMBL24320321 | 0.79 | TDP1 (0.44) | PTGER4HDAC1TDP1HDAC3HDAC2 | |
| SCHEMBL26914476 | 0.79 | TDP1 (0.44) | PTGER4HDAC1TDP1HDAC3HDAC2 | |
| SCHEMBL3926362 | 0.77 | PTGER4 (0.49) | PTGER4HDAC1HDAC3HDAC2LIPC | |
| SCHEMBL10048477 | 0.76 | PTGER4 (0.49) | PTGER4HDAC1HDAC3HDAC2 | |
| SCHEMBL3930758 | 0.76 | PTGER4 (0.51) | PTGER4ALDH1A1LIPCLIPGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1797077-A4 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2010526-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120101-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120101-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1797077-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| WO-2006033631-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | PTGER4 102/4885PIK3C3 2694/4885HDAC1 985/4885 |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | PTGER4 102/4885PIK3C3 2694/4885HDAC1 985/4885 |
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | PTGER4 76/4885PIK3C3 3964/4885HDAC1 699/4885 |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | PTGER4 39/4885PIK3C3 4640/4885HDAC1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.